{"content":"<li class=\"n-box-item date-title\" data-end=\"1500609599\" data-start=\"1500523200\" data-txt=\"Monday, December 23, 2019\">Thursday, July 20, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3280148\" data-ts=\"1500603932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280148-aeterna-zentaris-names-new-ceo-will-evaluate-strategic-alternatives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AEterna Zentaris names new CEO, will evaluate strategic alternatives</a></h4><ul><li>AEterna Zentaris (NASDAQ:<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a>) <font color='green'>+18.9%</font> AH after naming a new CEO and announcing a special committee to consider and <a href=\"https://seekingalpha.com/pr/16892828-aeterna-zentaris-forms-strategic-review-committee-appoints-michael-ward-ceo\" target=\"_blank\">evaluate various strategic and financing alternatives</a>.</li><li>AEZS also says David Dodd is out as President and CEO, effective immediately, with no explanation provided.</li><li>The new CEO is Michael Ward, who most recently was Chief Compliance  and Legal Officer and  Corporate Secretary for Sagent Pharmaceuticals.</li><li>Shares already had more than doubled since news <a href=\"https://seekingalpha.com/news/3279418-fda-accepts-aeternas-resubmitted-marketing-application-macrilen-action-date-december-30\" target=\"_blank\">after the close Tuesday</a> that the FDA accepted AEZS's new drug  application seeking approval of its Macrilen growth hormone drug.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280148\" data-linked=\"AEterna Zentaris names new CEO, will evaluate strategic alternatives\" data-tweet=\"$AEZS - AEterna Zentaris names new CEO, will evaluate strategic alternatives https://seekingalpha.com/news/3280148-aeterna-zentaris-names-new-ceo-will-evaluate-strategic-alternatives?source=tweet\" data-url=\"https://seekingalpha.com/news/3280148-aeterna-zentaris-names-new-ceo-will-evaluate-strategic-alternatives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280147\" data-ts=\"1500602636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280147-supervalu-declares-1-forminus-7-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supervalu declares 1-for-7 reverse split</a></h4><ul>     <li>Supervalu (NYSE:<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a>) <font color='red'>-4.1%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16892791-supervalu-announces-1minus-7-reverse-stock-split\" target=\"_blank\">1-for-7 reverse stock split</a>, in a move it hopes will enhance the appeal of its shares to the financial community, including institutional investors.</li>     <li>SVU says the move will take effect at the close on Aug. 1, reducing the number of common shares to ~57.1M and the total shares issued and outstanding to 38.35M from 268.5M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280147\" data-linked=\"Supervalu declares 1-for-7 reverse split\" data-tweet=\"$SVU - Supervalu declares 1-for-7 reverse split https://seekingalpha.com/news/3280147-supervalu-declares-1-forminus-7-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3280147-supervalu-declares-1-forminus-7-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280144\" data-ts=\"1500594416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280144-pareteumplus-19_8-after-signing-new-cloud-customers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +19.8% after signing new cloud customers</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color='green'>gained 19.8%</font> today, continuing a week of roller-coaster moves, after announcing <a href=\"https://seekingalpha.com/pr/16891735-pareteum-signs-two-new-uk-based-customers-adding-1000-000-revenue-backlog-teum-global\" target=\"_blank\">two new customers</a> adding $1M in revenue backlog.</li>    <li>The two new UK-based customers are on cloud services contracts for Pareteum's on-demand hosted Home Location Register services, the second and third customers for the product.</li>    <li>The two deals run for three years each and represent more thna 50,000 subscriber equivalents.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280144\" data-linked=\"Pareteum +19.8% after signing new cloud customers\" data-tweet=\"$TEUM - Pareteum +19.8% after signing new cloud customers https://seekingalpha.com/news/3280144-pareteumplus-19_8-after-signing-new-cloud-customers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280144-pareteumplus-19_8-after-signing-new-cloud-customers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280142\" data-ts=\"1500593914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHCT\" target=\"_blank\">CHCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280142-community-healthcare-trust-prices-offering-23_45\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Community Healthcare Trust prices offering at $23.45</a></h4><ul>   <li>Community Healthcare Trust (<a href=\"http://seekingalpha.com/symbol/CHCT\" target=\"_blank\">CHCT</a> <font color='red'>-6%</font>) has <a href=\"https://seekingalpha.com/pr/16892916-community-healthcare-trust-incorporated-announces-pricing-public-offering-common-stock\" target=\"_blank\">priced a public offering</a> of shares at $23.45, today's closing price.</li>    <li>The share price has <font color='red'>fallen 9.8%</font> in two days since the company announced the offering.</li>    <li>The company's offering 4.25M shares, for net proceeds of about $94.6M.</li>    <li>Underwriters have a 30-day greenshoe option for up to 637,500 more shares.</li>    <li>Proceeds are expected to repay the company's revolving credit, fund future acquisitions and for general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280142\" data-linked=\"Community Healthcare Trust prices offering at $23.45\" data-tweet=\"$CHCT - Community Healthcare Trust prices offering at $23.45 https://seekingalpha.com/news/3280142-community-healthcare-trust-prices-offering-23_45?source=tweet\" data-url=\"https://seekingalpha.com/news/3280142-community-healthcare-trust-prices-offering-23_45\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280136\" data-ts=\"1500588589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280136-ebayminus-5_1-investors-take-in-expected-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EBay -5.1% as investors take in as-expected Q2</a></h4><ul>   <li>EBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>) is <font color='red'>5.1% lower</font> postmarket after <a href=\"https://seekingalpha.com/news/3280037-ebay-eps-line-beats-revenue\" target=\"_blank\">Q2 earnings</a> largely in line with expectations but that indicated slow activity growth and unsurprising guidance ahead.</li>    <li>The stock had gained 21% this year and more than 14% over the past three months as investors anticipated a healthy quarter.</li>    <li>Gross merchandise volume came to $21.5B (up 3%; up 5% in constant currency) while revenue grew 4%. The company added 2M active buyers across platforms to arrive at 171M global active buyers.</li>    <li>The board has approved an additional $3B in stock repurchase authorization.</li>    <li>It's guiding to Q3 revenues of $2.35B-$2.39B (organic growth of 6-8%), above consensus for $2.32B, and EPS of $0.46-$0.48, vs. consensus for $0.48. For the full year, it sees revenues of $9.3B-$9.5B (vs. consensus for $9.42B) and EPS of $1.98-$2.03 (vs. consensus for $2.01).</li>    <li><a href=\"https://seekingalpha.com/pr/16892706-ebay-inc-reports-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3280136\" data-linked=\"EBay -5.1% as investors take in as-expected Q2\" data-tweet=\"$EBAY - EBay -5.1% as investors take in as-expected Q2 https://seekingalpha.com/news/3280136-ebayminus-5_1-investors-take-in-expected-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3280136-ebayminus-5_1-investors-take-in-expected-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280129\" data-ts=\"1500586502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280129-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a> <font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a> <font color='green'>+4.2%</font>. <a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a> <font color='green'>+4.1%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color='green'>+3.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/SMCI' title='Super Micro Computer, Inc.'>SMCI</a> <font color='red'>-9.5%</font>. <a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a> <font color='red'>-9.3%</font>. <a href='https://seekingalpha.com/symbol/NCR' title='NCR Corporation'>NCR</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a> <font color='red'>-5.2%</font>. <a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a> <font color='red'>-4.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280129\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ATHN $SKX $COF - After Hours Gainers / Losers https://seekingalpha.com/news/3280129-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3280129-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280125\" data-ts=\"1500585939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCR\" target=\"_blank\">NCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280125-ncr-misses-q2-revenue-software-atm-weakness-shares-down-7_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NCR misses Q2 revenue with software, ATM weakness; shares down 7.1%</a></h4><ul><li>        NCR (NYSE:<a href='https://seekingalpha.com/symbol/NCR' title='NCR Corporation'>NCR</a>) reports Q2 results with an EPS beat and a miss on revenue. Software revenue grew 3% on the year to $464M due to a 9% cloud growth. Net annual contract value was $18M, up 13%.</li><li>               Other segment performance: Software License: $77M (-6%); Software Maintenance: $91M (flat); Cloud: $145M (+9%); and Professional Services: $151M (+3%).&nbsp;</li><li>               ATM revenue dropped 21% with the company expecting a recovery due to upcoming large customer contracts. IPS revenue dropped 91% due to the divestiture.&nbsp;</li><li>Cash: cash from operating activities reported at $95M and FCF at $18M as the company uses working capital to drive revenue projects later this year.&nbsp;</li><li>        Q3 guidance: revenue of $1.66B to $1.7B, compared to $1.73B consensus, and EPS between $0.88 and $0.93, which matches consensus at the upper end.</li><li>               FY17 guidance reiterated: revenue between $6.63B and $6.75B, with consensus at $6.68B, and EPS of $3.32 to $3.42, which straddles the $3.37 consensus. &nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16892694-ncr-announces-second-quarter-2017-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>               NCR shares are&nbsp;<font color='red'>down 7.1%</font>&nbsp;aftermarket.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280038-ncr-beats-0_04-misses-revenue\" target=\"_blank\">NCR beats by $0.04, misses on revenue</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280125\" data-linked=\"NCR misses Q2 revenue with software, ATM weakness; shares down 7.1%\" data-tweet=\"$NCR - NCR misses Q2 revenue with software, ATM weakness; shares down 7.1% https://seekingalpha.com/news/3280125-ncr-misses-q2-revenue-software-atm-weakness-shares-down-7_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3280125-ncr-misses-q2-revenue-software-atm-weakness-shares-down-7_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280124\" data-ts=\"1500585918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANET\" target=\"_blank\">ANET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280124-aristaminus-4_3-itc-keeps-cisco-related-import-ban-in-place\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arista -4.3% as ITC keeps Cisco-related import ban in place</a></h4><ul>   <li>Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) has <font color='red'>slipped 4.3%</font> after hours after the International Trade Commission has denied its request to set aside a ban on product imports following rulings that two Cisco Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) patents are invalid.</li>    <li>Rulings by the Patent Trial and Appeal Board aren't a final step and don't reflect a \"changed circumstance such that the remedial orders should be rescinded,\" the ITC said.</li>    <li>Appeals that Cisco is undertaking will come before the Patent and Trademark Office elects to formally cancel Cisco's patents. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3280124\" data-linked=\"Arista -4.3% as ITC keeps Cisco-related import ban in place\" data-tweet=\"$ANET $ANET $CSCO - Arista -4.3% as ITC keeps Cisco-related import ban in place https://seekingalpha.com/news/3280124-aristaminus-4_3-itc-keeps-cisco-related-import-ban-in-place?source=tweet\" data-url=\"https://seekingalpha.com/news/3280124-aristaminus-4_3-itc-keeps-cisco-related-import-ban-in-place\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280120\" data-ts=\"1500585411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTX\" target=\"_blank\">PTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280120-pernix-sees-drop-in-revenues-for-q2-shares-slip-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pernix sees drop in revenues for Q2; shares slip 5% after hours</a></h4><ul><li>Pernix Therapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a>) is down&nbsp;<font color='red'>5%&nbsp;</font>after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16892816-pernix-therapeutics-pre-announces-certain-preliminary-second-quarter-2017-financial-results\" target=\"_blank\">announcement</a> of preliminary Q2 results.</li><li>The company expects revenues of $33.0M - 35.0M, down 5 - 10% yoy. Net loss should be ($20.5M - 24.5M) while non-GAAP EBITDA should be $4.5M - 6.0M. Quarter-end quick assets were $14.3M.</li><li>Silenor prescriptions were down 4% yoy, Treximet scripts were down 7% as were Zohydro ER's.</li><li>Complete results will be released on July 27.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280120\" data-linked=\"Pernix sees drop in revenues for Q2; shares slip 5% after hours\" data-tweet=\"$PTX $PTX-OLD - Pernix sees drop in revenues for Q2; shares slip 5% after hours https://seekingalpha.com/news/3280120-pernix-sees-drop-in-revenues-for-q2-shares-slip-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3280120-pernix-sees-drop-in-revenues-for-q2-shares-slip-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280115\" data-ts=\"1500584887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTAS\" target=\"_blank\">CTAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280115-cintasplus-2_2-g-and-k-acquisition-boosts-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cintas +2.2% as G&amp;K acquisition boosts revenues</a></h4><ul>    <li>Uniform company Cintas (<a href=\"http://seekingalpha.com/symbol/CTAS\" target=\"_blank\">CTAS</a> <font color='green'>+0.6%</font>) is picking up in after-hours trade, <font color='green'>+2.2%</font>, after largely <a href=\"https://seekingalpha.com/news/3280051-cintas-beats-0_13-revenue-line\" target=\"_blank\">in-line fiscal Q4 results</a> that got a sales boost from the company's acquisition of G&amp;K.</li>    <li>Revenue grew 23% with the help of $187.7M from G&amp;K. Organic growth was 8.1%; by segment, organic growth was 8% for Uniform Rental and Facility Services, and 9.2% for First Aid and Safety Services.</li>    <li>Operating income, meanwhile, fell 11.2% to $177.3M, hit by $63.7M of transaction and integration expenses from the acquisition.</li>    <li>Revenue breakout: Uniform rental and facility services, $1.22B (up 27.1%); Other, $310.3M (up 9.3%).</li>    <li>For fiscal 2018, it's guiding to revenues of $6.27B-$6.36B (light of consensus for $6.44B) and EPS of $5.15-$5.25 (above expectations for $4.99).</li>    <li><a href=\"https://seekingalpha.com/pr/16892703-cintas-corporation-announces-fiscal-2017-fourth-quarter-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3280115\" data-linked=\"Cintas +2.2% as G&amp;K acquisition boosts revenues\" data-tweet=\"$CTAS - Cintas +2.2% as G&amp;K acquisition boosts revenues https://seekingalpha.com/news/3280115-cintasplus-2_2-g-and-k-acquisition-boosts-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3280115-cintasplus-2_2-g-and-k-acquisition-boosts-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280093\" data-ts=\"1500583618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MXIM\" target=\"_blank\">MXIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280093-maxim-integrated-reports-mixed-q4-weak-guidance-shares-down-5_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxim Integrated reports mixed Q4, weak guidance; shares down 5.5%</a></h4><ul><li>        Maxim Integrated (NASDAQ:<a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a>) reports Q4 results with an EPS beat and revenue miss.</li><li>               Cash: Cash flow from operations reported at $237M, and Maxim ended the quarter with $2.74B in cash and equivalents.&nbsp;</li><li>               Dividend: Quarterly dividend increased 9% to $0.36 per share payable on September 14 to stockholders of record on August 31.</li><li>               New share repurchase authorization for $1B.&nbsp;&nbsp;</li><li>               Q1 outlook: revenue between $555M and $595M compared to $592.68M consensus, EPS between $0.52 and $0.58, which matches consensus at the high end, and gross margins between 65% and 68%.&nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16892648-maxim-integrated-reports-results-fourth-quarter-fiscal-2017-increases-dividend-9-percent\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Maxim Integrated shares are&nbsp;<font color='red'>down 5.5%&nbsp;</font>aftermarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280032-maxim-integrated-products-beats-0_01-misses-revenue\" target=\"_blank\">Maxim Integrated Products beats by $0.01, misses on revenue</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3280093\" data-linked=\"Maxim Integrated reports mixed Q4, weak guidance; shares down 5.5%\" data-tweet=\"$MXIM - Maxim Integrated reports mixed Q4, weak guidance; shares down 5.5% https://seekingalpha.com/news/3280093-maxim-integrated-reports-mixed-q4-weak-guidance-shares-down-5_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3280093-maxim-integrated-reports-mixed-q4-weak-guidance-shares-down-5_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280089\" data-ts=\"1500583550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKX\" target=\"_blank\">SKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280089-skechersminus-2-q2-profits-miss-despite-record-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skechers -2% as Q2 profits miss despite record revenue</a></h4><ul>   <li>Skechers (<a href=\"http://seekingalpha.com/symbol/SKX\" target=\"_blank\">SKX</a> <font color='red'>-0.9%</font>) is <font color='red'>off 2%</font> in postmarket trading after missing profit expectations in <a href=\"https://seekingalpha.com/news/3280021-skechers-misses-0_06-beats-revenue\" target=\"_blank\">Q2 earnings</a> as the company ramped up selling expenses including ad spending.</li>    <li>Revenues grew in double digits to a record and beat consensus, though, and gross margin was at 47.6%.</li>    <li>Selling expenses were up 32% due to ad spending at home and worldwide and selling commissions from its South Korean joint venture. G&amp;A expenses rose another 25.5%.</li>    <li>The company opened 31 stores in the second quarter.</li>    <li>Cash and equivalents were $751.6M (up 19.5% Y/Y); inventory was at $669.7M (up 13.4%, due to worldwide growth and in line with backlogs).</li>    <li>It's guiding to record Q3 sales of $1.05B-$1.075B, vs. consensus for $1.059B, and EPS of $0.42-0.47 (below expectations for $0.56), assuming flat sales in domestic wholesale, and double-digit increases in international wholesale and company-owned retail.</li>    <li><a href=\"https://seekingalpha.com/pr/16892629-skechers-announces-second-quarter-2017-financial-results-record-net-sales\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3280089\" data-linked=\"Skechers -2% as Q2 profits miss despite record revenue\" data-tweet=\"$SKX - Skechers -2% as Q2 profits miss despite record revenue https://seekingalpha.com/news/3280089-skechersminus-2-q2-profits-miss-despite-record-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3280089-skechersminus-2-q2-profits-miss-despite-record-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280076\" data-ts=\"1500583001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHN\" target=\"_blank\">ATHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280076-athenahealth-q2-revenues-up-15-earnings-up-621-shares-up-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">athenahealth Q2 revenues up 15%; earnings up 621%; shares up 6% after hours</a></h4><ul><li>athenahealth (NASDAQ:<a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a>) <a href=\"https://seekingalpha.com/pr/16892603-athenahealth-inc-reports-second-quarter-fiscal-year-2017-results\" target=\"_blank\">Q2 results</a> ($M): Revenues: 293.0 (+15.1%).</li><li>Net Income: 9.9 (+621.1%); Non-GAAP Net Income: 20.5 (+53.0%); EPS: 0.24 (+580.0%); Non-GAAP EPS: 0.51 (+50.0%).</li><li>Covered lives: 2,781,635 (+0.1%); discharge bed days: 14,107 (+24.3%).</li><li><strong>2017 guidance </strong>affirmed: Revenues: $1.21B 0 1.25B; operating income: $36M - 46M; non-GAAP operating income: $120M - 140M; annual bookings: $350M - 400M.</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280076\" data-linked=\"athenahealth Q2 revenues up 15%; earnings up 621%; shares up 6% after hours\" data-tweet=\"$ATHN - athenahealth Q2 revenues up 15%; earnings up 621%; shares up 6% after hours https://seekingalpha.com/news/3280076-athenahealth-q2-revenues-up-15-earnings-up-621-shares-up-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3280076-athenahealth-q2-revenues-up-15-earnings-up-621-shares-up-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280060\" data-ts=\"1500582512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COF\" target=\"_blank\">COF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280060-capital-one-up-nearly-5-after-cruising-past-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital One up nearly 5% after cruising past estimates</a></h4><ul><li>Q2 EPS after item of $1.96 vs. $1.69 a year ago, and topping expectations by $0.06.</li><li>Net revenue of $6.7B up 3%.</li><li>Noninterest expense down 1% to $3.4B; operating expenses down 2%, marketing expenses up 10%.</li><li>Provisions down 10% to $1.8B, with net charge-offs of $1.6B and $182M reserve build.</li><li>Net interest margin flat at 6.88%. Efficiency ratio after items of 50.75%.</li><li>Period-end loans up 2% to $244.3B; consumer banking loans of $75B up 1%; auto loans of $51.8B up 4%; home loans down 5% to $19.7B as portfolios run off.</li><li><a href=\"http://www.capitalone.com\" target=\"_blank\">Earnings cal at 5 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3280027-capital-one-financial-beats-0_06-beats-revenue\" target=\"_blank\">Capital One Financial beats by $0.06, beats on revenue</a> (July 20)</li><li><a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a> +4.8% after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3280060\" data-linked=\"Capital One up nearly 5% after cruising past estimates\" data-tweet=\"$COF - Capital One up nearly 5% after cruising past estimates https://seekingalpha.com/news/3280060-capital-one-up-nearly-5-after-cruising-past-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3280060-capital-one-up-nearly-5-after-cruising-past-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280047\" data-ts=\"1500581932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/V\" target=\"_blank\">V</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280047-visa-up-1_3-after-earnings-beat-boost-to-eps-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Visa up 1.3% after earnings beat, boost to EPS outlook</a></h4><ul><li>FQ3 payments volume of $1.9T was up 38% from a year ago. Cross-border volume growth up 11%, inclusive of Europe. Total processed transactions up 13%, inclusive of Europe.</li><li>17.8M shares bought back during quarter at an average price of $93.82 each. Another $5.5B of funds are available for share repurchase.</li><li>Full-year fiscal 2017 adjusted EPS growth now seen at about 20%.</li><li><a href=\"http://investor.visa.com\" target=\"_blank\">Conference call at 5 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3280022-visa-beats-0_05-beats-revenue\" target=\"_blank\">Visa beats by $0.05, beats on revenue</a> (July 20)</li><li><a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a><font color='green'> +1.3%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3280047\" data-linked=\"Visa up 1.3% after earnings beat, boost to EPS outlook\" data-tweet=\"$V - Visa up 1.3% after earnings beat, boost to EPS outlook https://seekingalpha.com/news/3280047-visa-up-1_3-after-earnings-beat-boost-to-eps-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3280047-visa-up-1_3-after-earnings-beat-boost-to-eps-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280041\" data-ts=\"1500581824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISRG\" target=\"_blank\">ISRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280041-intuitive-surgical-q2-top-line-up-13-earnings-up-20-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intuitive Surgical Q2 top line up 13%; earnings up 20%; shares up 1% after hours</a></h4><ul><li>Intuitive Surgical (NASDAQ:<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a>) <a href=\"https://seekingalpha.com/pr/16892642-intuitive-surgical-announces-second-quarter-earnings\" target=\"_blank\">Q2 results</a> ($M): Revenues: 756.2 (+12.8%); Instruments &amp; Accessories: 397.8 (+17.2%); Systems: 216.4 (+6.8%); Services: 142.0 (+10.9%).</li><li>Net Income: 221.5 (+20.1%); Non-GAAP Net Income: 228.4 (+3.6%); EPS: 5.77 (+22.5%); Non-GAAP EPS: 5.95 (+5.9%).</li><li>Shipments of <em>da Vinci</em> systems: 166 (+27.8%), global procedures up 16%.</li><li>Lower-priced <em>da Vinci </em><em>X</em> launched.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280041\" data-linked=\"Intuitive Surgical Q2 top line up 13%; earnings up 20%; shares up 1% after hours\" data-tweet=\"$ISRG - Intuitive Surgical Q2 top line up 13%; earnings up 20%; shares up 1% after hours https://seekingalpha.com/news/3280041-intuitive-surgical-q2-top-line-up-13-earnings-up-20-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3280041-intuitive-surgical-q2-top-line-up-13-earnings-up-20-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280033\" data-ts=\"1500581475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280033-microsoft-beats-0_27-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft beats by $0.27, beats on revenue</a></h4><ul><li>Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>): Q4 EPS of $0.98 <font color='green'>beats by $0.27</font>.</li><li>Revenue of $24.7B (+9.1% Y/Y) <font color='green'>beats by $430M</font>.</li><li>Shares <font color='green'>+1.5%</font>.</li><li><a href='https://www.microsoft.com/en-us/Investor/earnings/FY-2017-Q4/press-release-webcast'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280033\" data-linked=\"Microsoft beats by $0.27, beats on revenue\" data-tweet=\"$MSFT - Microsoft beats by $0.27, beats on revenue https://seekingalpha.com/news/3280033-microsoft-beats-0_27-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3280033-microsoft-beats-0_27-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280025\" data-ts=\"1500581238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETFC\" target=\"_blank\">ETFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280025-e-trade-financial-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">E*TRADE Financial beats by $0.04, beats on revenue</a></h4><ul><li>E*TRADE Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/ETFC' title='E*TRADE Financial Corporation'>ETFC</a>): Q2 EPS of $0.52 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $577M (+21.7% Y/Y) <font color='green'>beats by $23.37M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16892645-e-trade-financial-corporation-announces-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3280025\" data-linked=\"E*TRADE Financial beats by $0.04, beats on revenue\" data-tweet=\"$ETFC - E*TRADE Financial beats by $0.04, beats on revenue https://seekingalpha.com/news/3280025-e-trade-financial-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3280025-e-trade-financial-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280008\" data-ts=\"1500580775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESES\" target=\"_blank\">ESES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280008-eco-stim-energy-to-expand-oklahoma-pressure-pumping-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eco-Stim Energy to expand Oklahoma pressure pumping operations</a></h4><ul>     <li>Eco-Stim Energy (<a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='green'>+29%</font>) explodes higher after announcing a one-year agreement, with an option for a second year, with an unnamed U.S. E&amp;P company to <a href=\"https://seekingalpha.com/pr/16891547-eco-stim-energy-solutions-signs-second-contract-expand-operations-oklahoma-dedicated-crew-new\" target=\"_blank\">expand its pressure pumping operations in Oklahoma</a>.</li>     <li>ESES expects the work to support a second well stimulation crew allowing the company to further expand its footprint in the region.</li><li>ESES says the customer expects to complete 2-3 wells per month and is operating two drilling rigs in the region; each well is expected to be completed with ~25 stages and require ~40K HHP.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280008\" data-linked=\"Eco-Stim Energy to expand Oklahoma pressure pumping operations\" data-tweet=\"$ESES $ESES-OLD - Eco-Stim Energy to expand Oklahoma pressure pumping operations https://seekingalpha.com/news/3280008-eco-stim-energy-to-expand-oklahoma-pressure-pumping-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3280008-eco-stim-energy-to-expand-oklahoma-pressure-pumping-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280007\" data-ts=\"1500580714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WEB\" target=\"_blank\">WEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280007-web-com-shares-plunge-on-rumors-of-sale-cancellation-shares-down-7_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Web.com shares plunge on rumors of sale cancellation; shares down 7.7%</a></h4><ul><li>        Web.com (NASDAQ:<a href='https://seekingalpha.com/symbol/WEB' title='Web.com Group, Inc'>WEB</a>) shares plunge after saying the company will not move ahead with a sale, <a href=\"https://www.streetinsider.com/Mergers+and+Acquisitions/Web.com+Group+%28WEB%29+is+Said+to+Not+Move+Forward+with+Sale+Now+-+Bloomberg%2C+Citing+DealReporter/13115893.html\" target=\"_blank\">according</a> to the DealReporter. &nbsp;</li><li>           More information when available. </li><li> Web.com shares are down 7.72%.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3280007\" data-linked=\"Web.com shares plunge on rumors of sale cancellation; shares down 7.7%\" data-tweet=\"$WEB - Web.com shares plunge on rumors of sale cancellation; shares down 7.7% https://seekingalpha.com/news/3280007-web-com-shares-plunge-on-rumors-of-sale-cancellation-shares-down-7_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3280007-web-com-shares-plunge-on-rumors-of-sale-cancellation-shares-down-7_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280005\" data-ts=\"1500580589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUAN\" target=\"_blank\">NUAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280005-nuance-down-4-on-transcription-service-woes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuance down 4% on transcription service woes</a></h4><ul><li>Nuance Communications (<a href='https://seekingalpha.com/symbol/NUAN' title='Nuance Communications, Inc.'>NUAN</a> <font color='red'>-3.9%</font>) slumps on higher volume on a Bloomberg report that many doctors remain unable to use its transcription service three weeks after it was hit with a computer attack.</li><li>The company's eScription service at two major medical centers, Beth Israel in Boston and University of Pittsburgh, is still down.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280005\" data-linked=\"Nuance down 4% on transcription service woes\" data-tweet=\"$NUAN - Nuance down 4% on transcription service woes https://seekingalpha.com/news/3280005-nuance-down-4-on-transcription-service-woes?source=tweet\" data-url=\"https://seekingalpha.com/news/3280005-nuance-down-4-on-transcription-service-woes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280004\" data-ts=\"1500580184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCL\" target=\"_blank\">RCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280004-royal-caribbean-hits-52-week-high-j-p-morgan-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Royal Caribbean hits 52-week high as J.P. Morgan upgrades</a></h4><ul>     <li>Royal Caribbean (<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a> <font color='green'>+2.6%</font>) rolls to a new 52-week high after J.P. Morgan <a href=\"http://www.barrons.com/articles/royal-caribbean-cruises-dont-wait-for-weakness-1500576610\" target=\"_blank\">upgrades</a> shares to Overweight from Neutral with a $130 price target, raised from $111, even after the stock has surged 40%&nbsp;YTD.</li>     <li>JPM sees 2018 as another year of mid-to high teens EPS growth for RCL, driven by 3% capacity growth, 3% net yield growth and 1% new cruise costs growth.</li><li>The firm bases its upgrade on recent channel checks/survey work of continued strong operating (demand/pricing) momentum; reasonable valuation at ~13x forward year EPS which is below its long-term average; and a track record of Q3-Q4 seasonality where RCL shares typically outperform both the S&amp;P 500 and its peers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3280004\" data-linked=\"Royal Caribbean hits 52-week high as J.P. Morgan upgrades\" data-tweet=\"$RCL - Royal Caribbean hits 52-week high as J.P. Morgan upgrades https://seekingalpha.com/news/3280004-royal-caribbean-hits-52-week-high-j-p-morgan-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3280004-royal-caribbean-hits-52-week-high-j-p-morgan-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3280001\" data-ts=\"1500578792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMI\" target=\"_blank\">KMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3280001-kinder-morgan-gains-on-shareholder-friendly-moves-one-analyst-doubts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kinder Morgan gains on shareholder-friendly moves; one analyst has doubts</a></h4><ul>     <li>Kinder Morgan (<a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a> <font color='green'>+4.6%</font>) marches higher after unveiling plans to <a href=\"https://seekingalpha.com/news/3279654-kinder-morgan-pledges-60-percent-dividend-hike-next-year-rising-1-share-19\" target=\"_blank\">significantly raise its dividend</a> and buy back shares.</li>     <li>The dividend increase came as KMI reported Q2 profits of $337M, up a bit from $333M in the year-ago period, and distributable cash flow of $1.02B was off slightly from $1.05B in Q2 2016, driven by lower contributions from Southern Natural Gas as a result of last year's 50% sale of the pipeline.</li>     <li>Jeffries' Chris Sighinolfi - who rates the stock Neutral with a $20 price target - <a href=\"http://www.barrons.com/articles/kinder-morgan-sets-schedule-for-large-dividend-hikes-share-buybacks-1500559988\" target=\"_blank\">raises questions about the buyback</a>, saying \"KMI has no formal cadence of anticipated repurchase activity, no established target price for the buybacks, and will not be 'mechanically buying' at the market.\"</li><li>The analyst says he is \"confused about the relative attractiveness of repurchasing stock at ~11-12x EBITDA vs. investing in incremental&nbsp;organic expansions at ~6.9x, the stated average capital-to-EBITDA multiple of KMI&rsquo;s backlog.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3280001\" data-linked=\"Kinder Morgan gains on shareholder-friendly moves; one analyst has doubts\" data-tweet=\"$KMI - Kinder Morgan gains on shareholder-friendly moves; one analyst has doubts https://seekingalpha.com/news/3280001-kinder-morgan-gains-on-shareholder-friendly-moves-one-analyst-doubts?source=tweet\" data-url=\"https://seekingalpha.com/news/3280001-kinder-morgan-gains-on-shareholder-friendly-moves-one-analyst-doubts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279989\" data-ts=\"1500577207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279989-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SSNT' title='SilverSun Technologies, Inc.'>SSNT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SYNT' title='Syntel, Inc.'>SYNT</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/MATR' title='Mattersight Corporation'>MATR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DWCH' title='Datawatch Corporation'>DWCH</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EGOV' title='NIC Inc.'>EGOV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279989\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$SSNT $USAT $SYNT - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3279989-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279989-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279990\" data-ts=\"1500577150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHR\" target=\"_blank\">DHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279990-danaherminus-2-q2-earnings-beat-less-appears-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Danaher -2% as Q2 earnings beat less than it appears, analyst says</a></h4><ul>     <li>Danaher (<a href='https://seekingalpha.com/symbol/DHR' title='Danaher Corporation'>DHR</a> <font color='red'>-2%</font>) is down despite reporting better than expected <a href=\"https://seekingalpha.com/news/3279741-danaher-corporation-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a> and raising FY 2017 earnings guidance, seeing EPS of $3.90-$3.97 vs. $3.93 analyst consensus estimate and up from its prior outlook of&nbsp;$3.85-$3.95.</li>     <li>Wells Fargo <a href=\"http://www.barrons.com/articles/danaher-falls-despite-better-than-expected-q2-earnings-1500559125\" target=\"_blank\">reiterates its Market Perform rating</a> on the shares, saying the Q2 beat does not look quite as strong on closer inspection.</li>     <li>The firm explains that DHR&nbsp;beat revenue slightly on a dollar basis, but core growth appears to be slightly below consensus and guidance, and while full-year guidance was raised slightly, Q3 is below consensus; no major surprises are noted in Life Sciences or Diagnostics, except that DHR is discontinuing the Veris line to focus on Cepheid.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279990\" data-linked=\"Danaher -2% as Q2 earnings beat less than it appears, analyst says\" data-tweet=\"$DHR - Danaher -2% as Q2 earnings beat less than it appears, analyst says https://seekingalpha.com/news/3279990-danaherminus-2-q2-earnings-beat-less-appears-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3279990-danaherminus-2-q2-earnings-beat-less-appears-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279982\" data-ts=\"1500575219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HD\" target=\"_blank\">HD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279982-home-improvement-stocks-hammered-sears-amazon-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Home improvement stocks hammered by Sears-Amazon partnership</a></h4><ul>     <li>Shares of Home Depot (<a href='https://seekingalpha.com/symbol/HD' title='Home Depot, Inc.'>HD</a> <font color='red'>-4.1%</font>) and Lowe's (<a href='https://seekingalpha.com/symbol/LOW' title='Lowe&#39;s Companies, Inc.'>LOW</a> <font color='red'>-5%</font>) suffer their <a href=\"https://blogs.wsj.com/moneybeat/2017/07/20/sears-partnership-with-amazon-crushes-home-improvement-stocks/\" target=\"_blank\">worst showing of this year</a> after Sears (SHLD <font color='green'>+14.1%</font>) announced an agreement to <a href=\"https://seekingalpha.com/news/3279833-sears-says-kenmore-products-now-available-amazon-shares-spike-13-percent\" target=\"_blank\">sell its Kenmore line</a> of home appliances directly through Amazon; Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='red'>-3.5%</font>), which also sells appliances, and Whirlpool (<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a> <font color='red'>-4.3%</font>) also are down sharply.</li>     <li>If AMZN chooses to dive further into the appliance business,&nbsp;one of the few retail areas where it has yet to penetrate deeply, home improvement stocks could get hit further moving forward, <em>WSJ</em>'s Amrith Ramkumar writes.</li>     <li>But Baird analyst Peter  Benedict thinks the selloff <a href=\"https://thefly.com/landingPageNews.php?id=2581285&amp;headline=HD;LOW-Baird-sees-buying-opportunity-in-Home-Depot-and-Lowes\" target=\"_blank\">creates a buying opportunity</a>, believing the SHLD-AMZN partnership likely will have a limited impact on HD and LOW as other major appliance brands already sell on AMZN, though he admits the deal introduces \"improved competition\" from a brand both retailers do not carry.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279982\" data-linked=\"Home improvement stocks hammered by Sears-Amazon partnership\" data-tweet=\"$HD $HD $LOW - Home improvement stocks hammered by Sears-Amazon partnership https://seekingalpha.com/news/3279982-home-improvement-stocks-hammered-sears-amazon-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3279982-home-improvement-stocks-hammered-sears-amazon-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279978\" data-ts=\"1500574230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279978-wells-starts-neutral-stance-on-discovery-scripps-networks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells starts Neutral stance on Discovery, Scripps Networks</a></h4><ul>   <li>Wells Fargo has initiated coverage of Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) at Market Perform, noting a confusing story and recent <a href=\"https://seekingalpha.com/news/3279353-discovery-plus-9_4-percent-scripps-networks-plus-10_4-percent-report-merger-discussion\" target=\"_blank\">chatter about a merger with Scripps Networks Interactive</a> (<a href=\"http://seekingalpha.com/symbol/SNI\" target=\"_blank\">SNI</a> <font color='green'>+3.6%</font>) that the firm says <a href=\"http://www.barrons.com/articles/wells-fargo-starts-discovery-communications-at-hold-just-okay-1500561044\" target=\"_blank\">doesn't make much sense</a>.</li>    <li>Aside from a merger premium, fundamentals at Discovery are \"just okay,\" writes Marci Ryvicker and her team.</li>    <li>While domestic ad growth is fine (\"nothing special\"), she writes \"We worry a little bit about domestic affiliate fee growth. DISCA's domestic cable nets are mature - both in terms of margin (58% on avg.) and distribution. Unlike many of its peers, however, DISCA is not in a lot of the mainstream streaming bundles; instead choosing to focus on a non-sports package which has yet to launch, price, etc.\"</li>    <li>The company is one of the most exposed to continuous viewership declines, Ryvicker says, and she doesn't see a clear path to digital monetization. Meanwhile, heavy international exposure hasn't helped the stock due to low EBITDA margins.</li>    <li>Wells has a $28 price target, just 3% upside from today's price.</li>    <li>The firm also launched Scripps Networks at Market Perform with a price target of $82, implying 2.9% upside from today's higher price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279978\" data-linked=\"Wells starts Neutral stance on Discovery, Scripps Networks\" data-tweet=\"$DISCA $DISCA $SNI - Wells starts Neutral stance on Discovery, Scripps Networks https://seekingalpha.com/news/3279978-wells-starts-neutral-stance-on-discovery-scripps-networks?source=tweet\" data-url=\"https://seekingalpha.com/news/3279978-wells-starts-neutral-stance-on-discovery-scripps-networks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279975\" data-ts=\"1500573747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279975-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MPVD' title='Mountain Province Diamonds, Inc'>MPVD</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SHLM' title='A. Schulman, Inc.'>SHLM</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/IIIN' title='Insteel Industries, Inc.'>IIIN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279975\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ESES-OLD $AMRS $MPVD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3279975-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279975-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279961\" data-ts=\"1500570461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEY\" target=\"_blank\">KEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279961-nomura-buy-dip-in-keycorp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura: Buy the dip in KeyCorp</a></h4><ul><li>KeyCorp (NYSE:<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a>) topped estimates, but says loans should come in at the low end of the forecast $87B-$88B range for the full-year average.</li><li><a href=\"http://investor.key.com/Cache/1001225755.PDF?O=PDF&amp;T=&amp;Y=&amp;D=&amp;FID=1001225755&amp;iid=100334\" target=\"_blank\">Presentation slides, page 14</a></li><li>Nomura's Bill Carcache pins the decline on dilution concerns after the CEO didn't rule out another acquisition. Nevertheless, Carcache sees no reason for estimates to be cut. He reiterates his Buy rating and $23 price target.</li><li>Shares are currently&nbsp;<font color='red'>lower by 4.4%</font>&nbsp;to $18.23.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279754-keycorp-beats-0_02-beats-revenue\" target=\"_blank\">KeyCorp beats by $0.02, beats on revenue</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279961\" data-linked=\"Nomura: Buy the dip in KeyCorp\" data-tweet=\"$KEY - Nomura: Buy the dip in KeyCorp https://seekingalpha.com/news/3279961-nomura-buy-dip-in-keycorp?source=tweet\" data-url=\"https://seekingalpha.com/news/3279961-nomura-buy-dip-in-keycorp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279958\" data-ts=\"1500570005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279958-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/FPI' title='Farmland Partners Inc'>FPI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TBK' title='Triumph Bancorp'>TBK</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/HAWK' title='Blackhawk Network Holdings, Inc.'>HAWK</a> <font color='green'>+6%</font>. RSO <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/STC' title='Stewart Information Services Corporation'>STC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SLM' title='SLM Corporation'>SLM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GOOD' title='Gladstone Commercial Corporation'>GOOD</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279958\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$AMBC $FPI $TBK - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3279958-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279958-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279953\" data-ts=\"1500568848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279953-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/AVA' title='Avista Corporation'>AVA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SSNT' title='SilverSun Technologies, Inc.'>SSNT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SYNT' title='Syntel, Inc.'>SYNT</a> <font color='green'>+13%</font>. SHLD <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HZO' title='MarineMax Inc.'>HZO</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SHLM' title='A. Schulman, Inc.'>SHLM</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/IIIN' title='Insteel Industries, Inc.'>IIIN</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/STC' title='Stewart Information Services Corporation'>STC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ADS' title='Alliance Data Systems Corporation'>ADS</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279953\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$AEZS $SRPT $AVA - Midday Gainers / Losers https://seekingalpha.com/news/3279953-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279953-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279951\" data-ts=\"1500568176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279951-vale-forecasts-2017-iron-ore-production-low-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale forecasts 2017 iron ore production at low end of guidance</a></h4><ul>     <li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-2.5%</font>) is lower after saying its iron ore production would <a href=\"http://www.reuters.com/article/us-vale-sa-output-idUSKBN1A51I1\" target=\"_blank\">close the year near the bottom</a> of its forecast of 360M-380M metric tons, despite <a href=\"http://www.vale.com/en/aboutvale/news/pages/2q17-production-report.aspx\" target=\"_blank\">reporting record Q2 production</a>.</li>     <li>Vale says it achieved a record for Q2 iron ore output of 91.85M metric tons, up 5.8% Y/Y, mainly due to the ramp-up of the S11D mines in the Northern System, and pellet production rose 21.5% to 12.2M metric tons.</li>     <li>The Northern System, which comprises the Caraj&aacute;s, Serra Leste and S11D mining areas, also hit a production record of 41.5M metric tons, up 13.7% Y/Y.</li>     <li>Vale says Q2 nickel production fell 16% Y/Y to 65.9K metric tons, mainly due to the reconstruction of a furnace and planned maintenance in Sudbury, Canada, and it cuts expected nickel output for the year from to 295K metric tons from 317K tons.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279951\" data-linked=\"Vale forecasts 2017 iron ore production at low end of guidance\" data-tweet=\"$VALE - Vale forecasts 2017 iron ore production at low end of guidance https://seekingalpha.com/news/3279951-vale-forecasts-2017-iron-ore-production-low-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279951-vale-forecasts-2017-iron-ore-production-low-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279949\" data-ts=\"1500567609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FPI\" target=\"_blank\">FPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279949-farmland-partners-up-nearly-8-after-topping-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Farmland Partners up nearly 8% after topping estimates</a></h4><ul><li>Prior to last night's Q2 report, the stock had been&nbsp;<font color='red'>down 20%</font>&nbsp;for the year - mostly since May - suggesting plenty of bad news already baked in. The American Farmland purchase took place in Q1, so Q2 and the rest of the year should reflect the positives from that.</li><li>Q2 adjusted FFO of $3.7M or $0.10 per share was up from $1.2M and $0.06 a year earlier. Adjusted EBITDA of $8.1M up from $4M.</li><li><a href='https://seekingalpha.com/symbol/FPI' title='Farmland Partners Inc'>FPI</a>&nbsp;<font color='green'>+7.6%</font>&nbsp;on the session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279685-farmland-partners-beats-0_01-beats-revenue\" target=\"_blank\">Farmland Partners beats by $0.01, beats on revenue</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279949\" data-linked=\"Farmland Partners up nearly 8% after topping estimates\" data-tweet=\"$FPI - Farmland Partners up nearly 8% after topping estimates https://seekingalpha.com/news/3279949-farmland-partners-up-nearly-8-after-topping-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3279949-farmland-partners-up-nearly-8-after-topping-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279943\" data-ts=\"1500566581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHL\" target=\"_blank\">SCHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279943-scholasticminus-1_6-childrens-book-business-declines-post-potter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scholastic -1.6% as children&#39;s book business declines post-&#39;Potter&#39;</a></h4><ul>   <li>Scholastic (NASDAQ:<a href='https://seekingalpha.com/symbol/SCHL' title='Scholastic Corporation'>SCHL</a>) is <font color='red'>1.6% lower</font> after some choppy morning trading following fiscal Q4 earnings where the company <a href=\"https://seekingalpha.com/news/3279775-scholastic-beats-0_22-misses-revenue\" target=\"_blank\">beat profit expectations</a> but missed on revenues that fell nearly 3%.</li>    <li>Operating income rose 10% to $64.2M on increased education sales along with lower costs.</li>    <li>Revenue breakout: Children's Book Publishing and Distribution, $282.8M (down 6%); Education, $126.3M (up 12%); International, $90.5M (down 10%).</li>    <li>With the absence of new <i>Harry Potter</i> titles, for fiscal 2018, it's guiding to revenue of $1.65B-$1.7B and a \"commensurate decline\" in operating profits. Excluding <i>Potter</i> impact from this year, it sees operating income growing by double digits.'</li>    <li>It's forecasting EPS of $1.20-$1.30, excluding one-time items and a noncash pension curtailment charge. Free cash flow is expected at -$10M to -$20M, with an increase in capex from upgrading its SoHo headquarters as well as strategic tech investments.</li>    <li><a href=\"https://seekingalpha.com/pr/16891625-scholastic-reports-q4-fiscal-2017-results-fiscal-2018-outlook\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3279943\" data-linked=\"Scholastic -1.6% as children&#39;s book business declines post-&#39;Potter&#39;\" data-tweet=\"$SCHL - Scholastic -1.6% as children&#39;s book business declines post-&#39;Potter&#39; https://seekingalpha.com/news/3279943-scholasticminus-1_6-childrens-book-business-declines-post-potter?source=tweet\" data-url=\"https://seekingalpha.com/news/3279943-scholasticminus-1_6-childrens-book-business-declines-post-potter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279941\" data-ts=\"1500566494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279941-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CAW' title='CCA Industries Inc'>CAW</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/POOL' title='Pool Corporation'>POOL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BC' title='Brunswick Corporation'>BC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279941\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$MNRO $CAW $ADOM - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3279941-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279941-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279903\" data-ts=\"1500564691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279903-healthcare-top-5-gainers-losers-of-11-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:30</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+17%</font>.<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279903\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:30\" data-tweet=\"$SRPT $DFFN $AEZS - Healthcare - Top 5 Gainers / Losers as of 11:30 https://seekingalpha.com/news/3279903-healthcare-top-5-gainers-losers-of-11-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3279903-healthcare-top-5-gainers-losers-of-11-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279928\" data-ts=\"1500564476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRIO\" target=\"_blank\">DRIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279928-fda-clears-dariohealth-app-on-android-devices-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears DarioHealth app on Android devices; shares ahead 2%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16891817-dariohealth-receives-u-s-fda-clearance-certain-leading-android-devices-u-s\" target=\"_blank\">grants </a>510(k) clearance for DarioHealth's (<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color='green'>+1.8%</font>) app on certain leading Android mobile devices, including the Samsung Galaxy S series, Samsung Galaxy Note series and LG G series.</li><li>The approval enables the company to expand sales of its Dario Blood Glucose Monitoring System since it had been marketed exclusively for Apple's iOS 6.1 platform and higher since December 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279928\" data-linked=\"FDA clears DarioHealth app on Android devices; shares ahead 2%\" data-tweet=\"$DRIO - FDA clears DarioHealth app on Android devices; shares ahead 2% https://seekingalpha.com/news/3279928-fda-clears-dariohealth-app-on-android-devices-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279928-fda-clears-dariohealth-app-on-android-devices-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279925\" data-ts=\"1500563874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IHRTQ\" target=\"_blank\">IHRTQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279925-iheartmediaminus-7_4-exchange-offer-extended-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IHeartMedia -7.4% as exchange offer extended again</a></h4><ul>   <li>IHeartMedia (IHRT) is <font color='red'>off 7.4%</font> on relatively heavy volume after it again extended deadlines to take part in private term loan offers.</li>    <li>Talks with creditors have been ongoing for months as the firm faced nearly $350M in debt coming due this year.</li>    <li>The latest extension is to Aug. 4; some $45.5M in existing notes (about 0.6% of outstanding) had been tendered as of yesterday evening, not significantly different from the <a href=\"https://seekingalpha.com/news/3269968-iheartcommunications-extends-offers-term-loan-private-offers\" target=\"_blank\">tender in late May</a>.</li>    <li>Bloomberg noted that negotiations with a large creditor group seemed to arrive at a stalemate before tomorrow's original expiration of the latest offer.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279925\" data-linked=\"IHeartMedia -7.4% as exchange offer extended again\" data-tweet=\"$IHRTQ $IHRT - IHeartMedia -7.4% as exchange offer extended again https://seekingalpha.com/news/3279925-iheartmediaminus-7_4-exchange-offer-extended-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3279925-iheartmediaminus-7_4-exchange-offer-extended-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279924\" data-ts=\"1500563755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALPN\" target=\"_blank\">ALPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279924-nivalis-shareholders-back-merger-alpine-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nivalis shareholders back merger with Alpine; shares up 1%</a></h4><ul><li>At a special meeting yesterday, Nivalis Therapeutics (NVLS <font color='green'>+1.3%</font>) shareholders overwhelmingly <a href=\"https://seekingalpha.com/pr/16891562-nivalis-therapeutics-announces-results-special-meeting-stockholders\" target=\"_blank\">supported </a>its planned merger with Alpine Immune Sciences. The merger should close on July 24, after which the combined company will do business as Alpine Immune Sciences, Inc. Shares will trade under the symbol \"ALPN\" starting on July 25.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257764-nivalis-therapeutics-merge-alpine-immune-sciences\" target=\"_blank\">Nivalis Therapeutics to merge with Alpine Immune Sciences</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279924\" data-linked=\"Nivalis shareholders back merger with Alpine; shares up 1%\" data-tweet=\"$ALPN - Nivalis shareholders back merger with Alpine; shares up 1% https://seekingalpha.com/news/3279924-nivalis-shareholders-back-merger-alpine-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3279924-nivalis-shareholders-back-merger-alpine-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279923\" data-ts=\"1500563696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279923-reports-of-illness-from-virginia-chipotle-location-continue-to-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reports of illness from Virginia Chipotle location continue to rise</a></h4><ul>     <li>Chipotle Mexican Grill (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='red'>-1.7%</font>) moves lower as its recent <a href=\"https://seekingalpha.com/news/3279217-chipotle-shuts-restaurant-customers-become-ill-shares-minus-4-percent\" target=\"_blank\">food safety incident in Virginia</a> may be <a href=\"https://www.wsj.com/articles/over-100-report-being-sickened-at-virginia-chipotle-1500559449\" target=\"_blank\">worse than first realized</a>, with the number of reports of illness associated with the store continue to rise.</li>     <li>As of late Wednesday night, the founder of the iwaspoisoned.com food poisoning website said he had received reports of 133 people sickened at the CMG restaurant in Sterling, Va.</li>     <li>The director of the Loudoun County Health Department, which handles reports of illnesses in Sterling, says his office so far has received ~60 reports of people getting sick from the restaurant but that foodborne illnesses tend to be underreported.</li><li>Meanwhile, reports say <a href=\"http://www.cnbc.com/2017/07/20/rodents-reportedly-fall-from-ceiling-of-dallas-chipotle.html\" target=\"_blank\">rodents were spotted</a> at one of CMG's Dallas-area restaurants, with some customers claiming  their lunch was \"ruined by rodents falling from the ceiling\" on Tuesday.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279923\" data-linked=\"Reports of illness from Virginia Chipotle location continue to rise\" data-tweet=\"$CMG - Reports of illness from Virginia Chipotle location continue to rise https://seekingalpha.com/news/3279923-reports-of-illness-from-virginia-chipotle-location-continue-to-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3279923-reports-of-illness-from-virginia-chipotle-location-continue-to-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>136&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279919\" data-ts=\"1500563086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MASI\" target=\"_blank\">MASI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279919-masimos-rpvi-ce-mark-certified-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Masimo&#39;s RPVI CE Mark certified; shares up 1%</a></h4><ul><li>Masimo (<a href='https://seekingalpha.com/symbol/MASI' title='Masimo Corporation'>MASI</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/16891496-masimo-announces-ce-marking-noninvasive-rpvi-rainbow-multi-wavelength-index-pleth-variability\" target=\"_blank\">announces </a>the CE Marking of RPVI, a noninvasive and continuous measurement of the dynamic changes in perfusion index that occur during the respiratory cycle.</li><li>RPVI is a multi-wave version of the currently available Pleth Variability Index and is designed to provide enhanced specificity to changes in fluid volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279919\" data-linked=\"Masimo&#39;s RPVI CE Mark certified; shares up 1%\" data-tweet=\"$MASI - Masimo&#39;s RPVI CE Mark certified; shares up 1% https://seekingalpha.com/news/3279919-masimos-rpvi-ce-mark-certified-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3279919-masimos-rpvi-ce-mark-certified-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279913\" data-ts=\"1500562567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279913-diffusion-pharma-completes-production-milestone-for-late-stage-study-of-tsc-in-brain-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion Pharma completes production milestone for late-stage study of TSC in brain cancer; shares ahead 23%</a></h4><ul><li>Thinly traded nano cap Diffusion Pharmaceutics (<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+22.7%</font>) jumps on a whopping 78x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16891901-diffusion-pharmaceuticals-achieves-drug-production-milestone-planned-phase-3-clinical-trial\" target=\"_blank\">announcement</a> that it has completed a major production run of lead product candidate trans sodium crocetinate &#40;TSC&#41; which will be used to in its Phase 3 clinical trial in patients with newly diagnosed inoperable glioblastoma &#40;GBM&#41;. The study should commence by year-end.</li><li>A Phase 2 study showed GBM patients treated with TSC experienced almost a four-fold increase in survival compared to historical controls.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279913\" data-linked=\"Diffusion Pharma completes production milestone for late-stage study of TSC in brain cancer; shares ahead 23%\" data-tweet=\"$DFFN - Diffusion Pharma completes production milestone for late-stage study of TSC in brain cancer; shares ahead 23% https://seekingalpha.com/news/3279913-diffusion-pharma-completes-production-milestone-for-late-stage-study-of-tsc-in-brain-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3279913-diffusion-pharma-completes-production-milestone-for-late-stage-study-of-tsc-in-brain-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279909\" data-ts=\"1500561865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INNV\" target=\"_blank\">INNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279909-innovus-pharmas-zestra-okd-in-australia-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovus Pharma&#39;s Zestra OK&#39;d in Australia; shares up 1%</a></h4><ul><li>Innovus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INNV' title='Innovus Pharmaceuticals, Inc.'>OTCQB:INNV</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/16891563-innovus-pharma-s-partner-luminarie-receives-approval-zestra-female-sexual-arousal-disorder\" target=\"_blank\">announces </a>that licensee Luminarie Pty Ltd has received regulatory approval in Australia to market Zestra for the treatment of Female Sexual Arousal Disorder.</li><li>Luminarie also has commercialization rights in New Zealand and the Philippines.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269050-innovus-pharma-inks-zestra-distribution-deal-asia-pacific-shares-ahead-5-percent\" target=\"_blank\">Innovus Pharma inks Zestra distribution deal in Asia-Pacific; shares ahead 5%</a> (May 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279909\" data-linked=\"Innovus Pharma&#39;s Zestra OK&#39;d in Australia; shares up 1%\" data-tweet=\"$INNV - Innovus Pharma&#39;s Zestra OK&#39;d in Australia; shares up 1% https://seekingalpha.com/news/3279909-innovus-pharmas-zestra-okd-in-australia-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3279909-innovus-pharmas-zestra-okd-in-australia-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279906\" data-ts=\"1500561237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279906-exelixis-up-2-on-settlement-of-cobimetinib-collaboration-spat-genentech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis up 2% on settlement of cobimetinib collaboration spat with Genentech</a></h4><ul><li>Exelixis (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+1.5%</font>) and development partner Genentech (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) have reached a <a href=\"https://seekingalpha.com/pr/16891619-exelixis-announces-settlement-dispute-genentech-regarding-companies-collaboration-agreement\" target=\"_blank\">settlement </a>in their dispute related to their collaboration agreement for cancer med COTELLIC (cobimetinib). The partners have agreed to amend their contract to revise the revenue and cost-sharing arrangements.</li><li>Under the terms of the updated agreement, Exelixis will continue to be entitled to an equal share of U.S. profits and losses which will decrease as sales ramp (per the original 2006 contract). Effective July 1, the revenue applied to the P&amp;L statement for the COTELLIC collaboration will be calculated using the average of the quarterly net selling prices of COTELLIC and any branded Genentech products prescribed with it. Exelixis will continue to share U.S. commercialization costs while Genentech's share will now be allocated to the collaboration P&amp;L based on the number of products in the combination.</li><li>Exelixis will continue to co-promote COTELLIC in the U.S., providing up to 25% of the salesforce. Ex-U.S., it remains eligible for sales-based royalties per the 2006 agreement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234085-update-dispute-exelixis-genentech\" target=\"_blank\">Update on dispute between Exelixis and Genentech</a> (Jan. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279906\" data-linked=\"Exelixis up 2% on settlement of cobimetinib collaboration spat with Genentech\" data-tweet=\"$EXEL $EXEL $RHHBY - Exelixis up 2% on settlement of cobimetinib collaboration spat with Genentech https://seekingalpha.com/news/3279906-exelixis-up-2-on-settlement-of-cobimetinib-collaboration-spat-genentech?source=tweet\" data-url=\"https://seekingalpha.com/news/3279906-exelixis-up-2-on-settlement-of-cobimetinib-collaboration-spat-genentech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279905\" data-ts=\"1500561013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279905-natural-gas-inventory-build-comes-in-lower-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory build comes in lower than expected</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+28 Bcf</strong> vs. +32 Bcf consensus, +57 Bcf last week.</li><li>Futures&nbsp;<font color='green'>+0.91%</font>&nbsp;to $3.094.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279905\" data-linked=\"Natural gas inventory build comes in lower than expected\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory build comes in lower than expected https://seekingalpha.com/news/3279905-natural-gas-inventory-build-comes-in-lower-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3279905-natural-gas-inventory-build-comes-in-lower-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279904\" data-ts=\"1500561002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLM\" target=\"_blank\">SHLM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279904-schulmanminus-19-after-slashing-full-year-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A. Schulman -19% after slashing full-year earnings guidance</a></h4><ul>     <li>A. Schulman (<a href='https://seekingalpha.com/symbol/SHLM' title='A. Schulman, Inc.'>SHLM</a> <font color='red'>-18.8%</font>) plunges nearly 20% after <a href=\"https://seekingalpha.com/pr/16891845-schulman-revises-fiscal-2017-guidance\" target=\"_blank\">cutting full-year earnings guidance</a> to margin compression in its European business and weakened operating results from previous forecasts in certain other regions.</li>     <li>SHLM now sees FY 2017 EPS of  $1.60-$1.70, much lower than its earlier guidance of $2.08-$2.18 and $2.03 analyst consensus estimate, as well as full-year adjusted EBITDA of $200M-$204M.</li>     <li>While volumes in Europe remain on track with expectations, SHLM says it is \"incurring significant margin pressure in the region due to the magnitude and timing of raw material cost increases... This compression compounds the macroeconomic headwinds and previously disclosed operational challenges thus making our full-year guidance unattainable.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3279904\" data-linked=\"A. Schulman -19% after slashing full-year earnings guidance\" data-tweet=\"$SHLM - A. Schulman -19% after slashing full-year earnings guidance https://seekingalpha.com/news/3279904-schulmanminus-19-after-slashing-full-year-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279904-schulmanminus-19-after-slashing-full-year-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279900\" data-ts=\"1500560088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279900-steel-stocks-open-lower-after-nucor-misses-on-q2-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel stocks open lower after Nucor misses on Q2 earnings</a></h4><ul>     <li>Nucor (<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='red'>-2.9%</font>) opens lower after <a href=\"https://seekingalpha.com/news/3279861-nucor-misses-0_06-beats-revenue\" target=\"_blank\">Q2 earnings</a> missed analyst estimates and came in at the low end of the company's earlier guidance of $1.00-$1.05, and the steelmaker says it sees Q3 earnings in a range similar to quarterly results in Q1.</li>     <li>NUE says it shipped 6.75M total tons to outside customers during Q2, up 2% Q/Q and 5% Y/Y, and the average sales price/ton rose 5% Q/Q and 17% Y/Y; average scrap and scrap substitute cost per ton used during Q2 was $313, 10% higher than in Q1.\u200b</li><li>NUE says market conditions for hot-rolled sheet products are \"challenging due to aggressive competition,\" but non-residential construction indicators suggest that construction activity will remain healthy through year-end.</li>               <li>NUE says it continues to gain ground in the automotive market and expects to continue the trend through the rest of the year.</li><li>Steel stocks (<a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a> <font color='red'>-1.1%</font>) are broadly lower in early trading: <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='red'>-3%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-1.8%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='red'>-1.1%</font>, <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='red'>-0.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279900\" data-linked=\"Steel stocks open lower after Nucor misses on Q2 earnings\" data-tweet=\"$NUE $NUE $SLX - Steel stocks open lower after Nucor misses on Q2 earnings https://seekingalpha.com/news/3279900-steel-stocks-open-lower-after-nucor-misses-on-q2-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3279900-steel-stocks-open-lower-after-nucor-misses-on-q2-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279897\" data-ts=\"1500559707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279897-biotechs-poised-for-breakout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs poised for breakout</a></h4><ul><li>The iShares Nasdaq Biotechnology ETF (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+0.6%</font>) is positioned to break out of a month-long consolidation. On a technical basis, a move beyond ~322.50 on high volume should bode well for an up move.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a> <font color='green'>+0.6%</font>)(<a href='https://seekingalpha.com/symbol/LABU' title='Direxion Daily S&P Biotech Bull 3x Shares ETF'>LABU</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/PBE' title='PowerShares Dynamic Biotechnology & Genome Portfolio ETF'>PBE</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/UBIO' title='ProShares UltraPro NASDAQ Biotechnology ETF'>UBIO</a> <font color='green'>+1.2%</font>)(<a href='https://seekingalpha.com/symbol/BBP' title='BioShares Biotechnology Products ETF'>BBP</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279897\" data-linked=\"Biotechs poised for breakout\" data-tweet=\"$IBB $XBI $FBT - Biotechs poised for breakout https://seekingalpha.com/news/3279897-biotechs-poised-for-breakout?source=tweet\" data-url=\"https://seekingalpha.com/news/3279897-biotechs-poised-for-breakout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279884\" data-ts=\"1500557935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPC\" target=\"_blank\">GPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279884-on-genuine-parts-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Genuine Parts&#39; Q2</a></h4><ul>     <li>Genuine Parts (<a href='https://seekingalpha.com/symbol/GPC' title='Genuine Parts Company'>GPC</a> <font color='red'>-0.3%</font>)&nbsp;reports Automotive group net sales rose 3.6% to $2.16B in <a href=\"https://seekingalpha.com/pr/16891947-genuine-parts-company-reports-sales-earnings-second-quarter-ended-june-30-2017\" target=\"_blank\">Q2</a>.</li>     <li>Industrial net sales grew 7.3% to $1.25B.</li>     <li>Office Products net sales up 4.7% to $504.4M.</li>     <li>Electrical/Electronic Materials net sales expanded 10.9% to $204.63M.</li>     <li>Gross margin rate improved 30 bps to 30.2%.</li>     <li>Operating margin rate slipped 20 bps to 8.5%.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Sales: +3% to +4%;&nbsp;Diluted EPS: $4.70 to $4.75.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3279884\" data-linked=\"More on Genuine Parts&#39; Q2\" data-tweet=\"$GPC - More on Genuine Parts&#39; Q2 https://seekingalpha.com/news/3279884-on-genuine-parts-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279884-on-genuine-parts-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279880\" data-ts=\"1500557476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INO\" target=\"_blank\">INO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279880-inovio-prices-stock-offering-6-shares-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio prices stock offering at $6; shares down 8%</a></h4><ul><li>Inovio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='red'>-7.7%</font>) <a href=\"https://seekingalpha.com/pr/16891469-inovio-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 12.5M shares of common stock at $6 per share. Underwriters over-allotment is an additional 1.875M shares. Closing date is July 25. Net proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279880\" data-linked=\"Inovio prices stock offering at $6; shares down 8%\" data-tweet=\"$INO - Inovio prices stock offering at $6; shares down 8% https://seekingalpha.com/news/3279880-inovio-prices-stock-offering-6-shares-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3279880-inovio-prices-stock-offering-6-shares-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279878\" data-ts=\"1500557324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BX\" target=\"_blank\">BX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279878-blackstone-earnings-rise-miss-estimates-shares-down-0_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blackstone earnings rise, but miss estimates; shares down 0.8%</a></h4><ul><li>Economic net income of $705M or $0.59 per share vs. $520M and $0.44 one year ago. Distributable income of $781.4M or $0.63 per share vs. $495M and $0.41 one year ago. Distribution is declared at $0.54 vs. $0.87 the previous quarter.</li><li>Management and advisory fees of $697M up 14% Y/Y; performance fees of $757M up 68%.</li><li>Total AUM of $371B up 4% Y/Y; fee-earning AUM of $281.9B up 6%.</li><li>$8.4B put to work in Q2; $20.2B YTD.</li><li><a href=\"http://www.blackstone.com/\" target=\"_blank\">Conference call at 11 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279774-blackstone-misses-0_03-misses-revenue\" target=\"_blank\">Blackstone misses by $0.03, misses on revenue</a> (July 20)</li><li><a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>&nbsp;<font color='red'>-0.8%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3279878\" data-linked=\"Blackstone earnings rise, but miss estimates; shares down 0.8%\" data-tweet=\"$BX - Blackstone earnings rise, but miss estimates; shares down 0.8% https://seekingalpha.com/news/3279878-blackstone-earnings-rise-miss-estimates-shares-down-0_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3279878-blackstone-earnings-rise-miss-estimates-shares-down-0_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279877\" data-ts=\"1500557156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVN\" target=\"_blank\">TRVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279877-trevena-expects-to-file-u-s-marketing-application-for-pain-med-olinvo-no-later-october\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trevena expects to file U.S. marketing application for pain med Olinvo no later than October; medical chief to depart next month; shares slip 4% premarket</a></h4><ul><li>Micro cap Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) is down&nbsp;<font color='red'>4%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16892054-trevena-host-2017-analyst-day-announce-results-athena-open-label-safety-study-olinvo\" target=\"_blank\">announcement </a>outlining the agenda for today's Analyst Day in New York.</li><li>Enrollment has been completed in the ATHENA study to support its U.S. marketing application for pain candidate OLINVO (oliceridine injection). The company expects to file its NDA in the September/October time frame.</li><li><a href=\"http://www.trevenainc.com/TRV130.php\" target=\"_blank\">Oliceridine</a>, a G-protein-biased ligand that targets the mu opioid receptor, is being developed as a potential replacement of intravenous opioid analgesics.&nbsp;Its value proposition is comparable pain relieving efficacy to morphine while minimizing the unwanted respiratory depression, GI dysfunction (constipation), nausea and vomiting.</li><li>Management will also discuss migraine candidate TRV250 (early-stage study results expected in H2) and a new preclinical lead optimization program targeting S1P receptors with a novel mechanism that has shown activity in preclinical models of chemo-induced peripheral neuropathy, neuropathic pain and inflammatory pain.</li><li>The company announces that chief medical officer David Soergel, M.D. will leave the company in late August to pursue another opportunity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255908-trevenas-lead-product-candidate-matches-iv-morphine-less-side-effects-late-stage-pain\" target=\"_blank\">Trevena's lead product candidate matches IV morphine with less side effects in late-stage pain management studies; shares ahead 9% premarket</a> (April 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279877\" data-linked=\"Trevena expects to file U.S. marketing application for pain med Olinvo no later than October; medical chief to depart next month; shares slip 4% premarket\" data-tweet=\"$TRVN - Trevena expects to file U.S. marketing application for pain med Olinvo no later than October; medical chief to depart next month; shares slip 4% premarket https://seekingalpha.com/news/3279877-trevena-expects-to-file-u-s-marketing-application-for-pain-med-olinvo-no-later-october?source=tweet\" data-url=\"https://seekingalpha.com/news/3279877-trevena-expects-to-file-u-s-marketing-application-for-pain-med-olinvo-no-later-october\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279875\" data-ts=\"1500556853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOD\" target=\"_blank\">GOOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279875-gladstone-commercial-down-6-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gladstone Commercial down 6% after share sale</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16892078-gladstone-commercial-corporation-announces-pricing-common-stock-offering\" target=\"_blank\">ended up selling</a> 1.15M shares at $20.52 each. The underwriters have an option to buy up to another 172.5K shares at that price.</li><li><a href='https://seekingalpha.com/symbol/GOOD' title='Gladstone Commercial Corporation'>GOOD</a>&nbsp;<font color='red'>-6.1%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279875\" data-linked=\"Gladstone Commercial down 6% after share sale\" data-tweet=\"$GOOD - Gladstone Commercial down 6% after share sale https://seekingalpha.com/news/3279875-gladstone-commercial-down-6-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3279875-gladstone-commercial-down-6-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279871\" data-ts=\"1500556586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279871-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16891225-contrafect-corporation-announces-proposed-public-offering-common-stock-warrants\" target=\"_blank\">announcing</a> public offering of common stock and warrants.</li><li><a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279610-ptc-eps-line-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279628-c-h-robinson-worldwide-misses-0_12-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CHKP' title='Check Point Software Technologies Ltd.'>CHKP</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279727-check-point-software-technologies-beats-0_04-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16891469-inovio-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing</a> common stock offering.</li><li><a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a>&nbsp;<font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/GOOD' title='Gladstone Commercial Corporation'>GOOD</a>&nbsp;<font color='red'>-6%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/16891190-gladstone-commercial-corporation-announces-common-stock-offering\" target=\"_blank\">announcing</a>&nbsp;common stock offering.</li><li><a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/SHW' title='The Sherwin-Williams Company'>SHW</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279776-sherwin-williams-misses-0_05-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/WES' title='Western Gas Partners, L.P.'>WES</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3279871\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CFRX $PTC $CHRW - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3279871-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279871-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279868\" data-ts=\"1500556436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279868-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+31%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16891901-diffusion-pharmaceuticals-achieves-drug-production-milestone-planned-phase-3-clinical-trial\" target=\"_blank\">completion</a> of a major production run of its lead drug candidate trans sodium crocetinate.</li><li>SHLD <font color='green'>+18%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279833-sears-says-kenmore-products-now-available-amazon-shares-spike-13-percent\" target=\"_blank\">launching</a>&nbsp;Kenmore products on Amazon.</li><li><a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+18%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3279595-sarepta-therapeutics-beats-0_45-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/AVA' title='Avista Corporation'>AVA</a> <font color='green'>+17%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3279658-avista-bought-hydro-one-53-share\" target=\"_blank\">acquired</a> by Hydro One (<a href='https://seekingalpha.com/symbol/HRNNF' title='Hydro One Ltd'>OTC:HRNNF</a>).</li><li><a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a> <font color='green'>+5%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3279780-ocwen-settles-class-action-suit-take-34m-36m-q2-charge\" target=\"_blank\">settling</a> class action suit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279868\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DFFN $SHLDQ $SRPT - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3279868-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279868-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279862\" data-ts=\"1500555984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BVXV\" target=\"_blank\">BVXV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279862-biondvax-universal-flu-vaccine-candidate-successful-in-mid-stage-study-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BiondVax universal flu vaccine candidate successful in mid-stage study; shares ahead 9% premarket</a></h4><ul><li>Thinly traded nano cap BiondVax Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BVXV' title='Biondvax Pharmaceuticals'>BVXV</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16891590-biondvax-reports-positive-phase-2b-clinical-trial-results-universal-flu-vaccine\" target=\"_blank\">announcement </a>of positive results from a Phase 2b clinical trial assessing universal flu vaccine candidate M-001. The study met both endpoints of safety and influenza-specific cellular immune responses.</li><li>The company intends to advance M-001 into Phase 3 development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279862\" data-linked=\"BiondVax universal flu vaccine candidate successful in mid-stage study; shares ahead 9% premarket\" data-tweet=\"$BVXV - BiondVax universal flu vaccine candidate successful in mid-stage study; shares ahead 9% premarket https://seekingalpha.com/news/3279862-biondvax-universal-flu-vaccine-candidate-successful-in-mid-stage-study-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3279862-biondvax-universal-flu-vaccine-candidate-successful-in-mid-stage-study-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279860\" data-ts=\"1500555930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHW\" target=\"_blank\">SHW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279860-sherwin-williams-down-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sherwin Williams down post Q2 results</a></h4><ul>     <li>Sherwin Williams (NYSE:<a href='https://seekingalpha.com/symbol/SHW' title='The Sherwin-Williams Company'>SHW</a>)&nbsp;reports same-store sales rose 4.9% in <a href=\"https://seekingalpha.com/pr/16891639-sherwin-williams-company-reports-2017-second-quarter-financial-results\" target=\"_blank\">Q2</a>.</li>     <li>The Americas group&nbsp;net sales up 8.7% to $2.44B.</li>     <li>Consumer brands group net sales grew 16% to $536.4M.</li>     <li>Performance coatings group&nbsp;net sales increased 48% to $761.1M.</li>     <li>Gross margin rate squeezed 430 bps to 46.5%.</li>     <li>SG&amp;A expense rate improved 190 bps to 30.7%.</li>     <li><b>Q3 Guidance</b>: Core net sales:&nbsp;low to mid single digit&nbsp;percentage growth;&nbsp;Diluted EPS: $3.7 to $4.1.</li>     <li><b>FY2017 Guidance</b>: Core net sales:&nbsp;mid single digit percentage growth;&nbsp;Diluted EPS: $12.3 to $12.7.</li>     <li>SHW&nbsp;<font color='red'>-4.93%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279860\" data-linked=\"Sherwin Williams down post Q2 results\" data-tweet=\"$SHW - Sherwin Williams down post Q2 results https://seekingalpha.com/news/3279860-sherwin-williams-down-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3279860-sherwin-williams-down-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279853\" data-ts=\"1500555240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279853-sell-side-shops-bullish-on-sarepta-after-q2-results-shares-up-18-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-side shops bullish on Sarepta after Q2 results; shares up 18% premarket</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) is up&nbsp;<font color='green'>18%</font>&nbsp;premarket on robust volume after it reported $35M in EXONDYS 51 sales for Q2 with expectations of 2017 sales as high as $130M. The consensus Q2 estimate was $22M.</li><li>Sell-siders are jumping on the bullish bandwagon after the Q2 beat. Needham has raised its 2017 estimate to $172M from $109M based on the acceleration in new patients. It believes EXONDYS 51 can achieve global sales of more than $500M, worth more than $2/share. It also believes the company can reach profitability as early as Q2 2018.</li><li>RBC has raised its price target on the stock to $64 (88% upside) from $60. Key additional catalyst is dystrophin data from the Exon 53 program later this year.</li><li>SunTrust has followed suit, raising its price target to $56 (65% upside) from $45.</li><li>Credit Suisse and Nomura are also positive, but Morgan Stanley is not on board. It maintains an Equal Weight rating and a price target of $33 (3% downside risk).</li><li>About 24% of Sarepta's float is sold short.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3279853\" data-linked=\"Sell-side shops bullish on Sarepta after Q2 results; shares up 18% premarket\" data-tweet=\"$SRPT - Sell-side shops bullish on Sarepta after Q2 results; shares up 18% premarket https://seekingalpha.com/news/3279853-sell-side-shops-bullish-on-sarepta-after-q2-results-shares-up-18-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279853-sell-side-shops-bullish-on-sarepta-after-q2-results-shares-up-18-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279851\" data-ts=\"1500555055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279851-euro-on-rise-draghi-speaks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Euro on the rise as Draghi speaks</a></h4><ul><li>\"A very substantial degree of monetary accommodation is still needed,\" says Mario Draghi, leading off his post-policy meeting press conference. The Q&amp;A is getting underway now.</li><li>Given some of the hawkish rhetoric by ECB officials in the weeks leading up to today, some had expected a change in the central bank's policy statement, or in the tone of Draghi's remarks. Thus far, they have neither. The euro (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXE' title='CurrencyShares Euro Trust ETF'>FXE</a>), nonetheless, is on the rise,&nbsp;<font color='green'>up 0.3%</font>&nbsp;to $1.1549. The Stoxx 600 (NYSEARCA:<a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>) is&nbsp;<font color='green'>higher by 0.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279800-ecb-leaves-policy-unchanged-draghi-press-conference-tap\" target=\"_blank\">ECB leaves policy unchanged; Draghi press conference on tap</a> (July 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279851\" data-linked=\"Euro on the rise as Draghi speaks\" data-tweet=\"$FXE $FEZ - Euro on the rise as Draghi speaks https://seekingalpha.com/news/3279851-euro-on-rise-draghi-speaks?source=tweet\" data-url=\"https://seekingalpha.com/news/3279851-euro-on-rise-draghi-speaks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279848\" data-ts=\"1500554817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBC\" target=\"_blank\">WBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279848-on-wabco-holdings-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on WABCO Holdings&#39; Q2</a></h4><ul>     <li>WABCO Holdings (NYSE:<a href='https://seekingalpha.com/symbol/WBC' title='WABCO Holdings Inc.'>WBC</a>)&nbsp;reports sales rose 10.4% in local currencies in <a href=\"https://seekingalpha.com/pr/16891603-wabco-reports-q2-2017-results-continues-strongly-outperform-global-commercial-vehicle-market\" target=\"_blank\">Q2</a>.</li>     <li>Adjusted gross margin rate down 30 bps to 31.4%.</li>     <li>SG&amp;A expense rate improved 20 bps to 12.3%.</li>     <li>Adjusted operating margin rate slipped 30 bps to 14.7%.</li>     <li><b>FY2017 Guidance</b>: Sales: $3.025B to $3.1B (+8% to +11% in local currencies); Adjusted operating margin rate: 14.3% to 14.7%; GAAP operating margin rate: 13.3% to 13.7%; Adjusted net income: $325.5M to $341.6M; GAAP net income: $308.8M to $324.9M; Adjusted EPS: $6.05 to $6.35; Diluted EPS: $5.74 to $6.04; Diluted shares&nbsp;outstanding: ~54M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279848\" data-linked=\"More on WABCO Holdings&#39; Q2\" data-tweet=\"$WBC - More on WABCO Holdings&#39; Q2 https://seekingalpha.com/news/3279848-on-wabco-holdings-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279848-on-wabco-holdings-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279833\" data-ts=\"1500553790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279833-sears-says-kenmore-products-now-available-on-amazon-shares-spike-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears says Kenmore products now available on Amazon; shares spike 13%</a></h4><ul>     <li>Sears (SHLD) <font color='green'>+13.4%</font> premarket after announcing it has <a href=\"https://seekingalpha.com/pr/16891786-sears-launches-kenmore-products-amazon-com-including-alexa-enabled-smart-appliances\" target=\"_blank\">launched Kenmore products on Amazon.com</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>), including the full line of Kenmore Smart appliances with Amazon Alexa.</li>     <li>SHLD says the move marks the broadest distribution of Kenmore outside of Sears branded stores and related online retail platforms.</li><li>SHLDi says distribution will be expanded nationwide to the full line of Kenmore home appliances; terms of the deal are not disclosed.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279833\" data-linked=\"Sears says Kenmore products now available on Amazon; shares spike 13%\" data-tweet=\"$SHLDQ $SHLDQ $AMZN - Sears says Kenmore products now available on Amazon; shares spike 13% https://seekingalpha.com/news/3279833-sears-says-kenmore-products-now-available-on-amazon-shares-spike-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3279833-sears-says-kenmore-products-now-available-on-amazon-shares-spike-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>105&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279832\" data-ts=\"1500553777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRWD\" target=\"_blank\">IRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279832-ironwood-gerd-candidate-successful-in-mid-stage-study-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ironwood GERD candidate successful in mid-stage study; shares ahead 4% premarket</a></h4><ul><li>Ironwood Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16891749-ironwood-pharmaceuticals-reports-positive-top-line-results-iwminus-3718-phase-iib-trial\" target=\"_blank\">announcement </a>of positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02637557?term=iw-3718&amp;rank=1\" target=\"_blank\">Phase 2b clinical trial</a> assessing IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease &#40;GERD&#41;.</li><li>The study met its primary endpoint of demonstrating a statistically valid change from baseline in heartburn severity at week 8 for twice-daily IW-3718 (1500 mg) plus a proton pump inhibitor &#40;PPI&#41; compared to a PPI alone. Specifically, IW-3718 + a PPI showed a mean decrease of 58.0% from baseline in heartburn severity versus 46.0% for a PPI alone (p=0.04). In addition, the IW-3718 1500 mg cohort experienced a mean decrease in weekly regurgitation frequency of 55.4% from baseline compared to 37.9% for a PPI alone (p=0.01) (in patients with baseline regurgitation).</li><li>The company plans to meet with the FDA to discuss the results and clarify the design of a Phase 3 study evaluating the 1500 mg dose.</li><li>IW-3718 is a gastric retentive formulation of a bile acid sequestrant that was developed with drug delivery technology licensed from Depomed called Acuform. It is designed to deliver the sequestrant to the stomach over an extended period of time where it intercepts bile before it reaches the esophagus.</li><li>Management will host a conference call momentarily to discuss the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279832\" data-linked=\"Ironwood GERD candidate successful in mid-stage study; shares ahead 4% premarket\" data-tweet=\"$IRWD - Ironwood GERD candidate successful in mid-stage study; shares ahead 4% premarket https://seekingalpha.com/news/3279832-ironwood-gerd-candidate-successful-in-mid-stage-study-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279832-ironwood-gerd-candidate-successful-in-mid-stage-study-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279810\" data-ts=\"1500552146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRV\" target=\"_blank\">TRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279810-weather-losses-behind-travelers-miss-shares-down-1_35-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weather losses behind Travelers miss; shares down 1.35% premarket</a></h4><ul><li>The company notes relatively high levels of catastrophe and non-catastrophe weather-related losses. The combined ratio of 96.7% includes 6.4 points of cat losses; underlying combined ratio &nbsp;of 93.5%. One year ago, the combined ratio was 93.1%, with underlying at 92.3%.</li><li>Net investment income of $598M up 6% thanks to strong private-equity returns.</li><li>Net written premiums of a record $6.64B were up 5%.</li><li>Adjusted book value per share of $82.71 vs. $80.44 a year ago.</li><li><a href=\"http://investor.travelers.com\" target=\"_blank\">Conference call at 9 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279769-travelers-companies-misses-0_19-beats-revenue\" target=\"_blank\">The Travelers Companies misses by $0.19, beats on revenue</a> (July 20)</li><li><a href='https://seekingalpha.com/symbol/TRV' title='The Travelers Companies, Inc.'>TRV</a>&nbsp;<font color='red'>-1.35%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279810\" data-linked=\"Weather losses behind Travelers miss; shares down 1.35% premarket\" data-tweet=\"$TRV - Weather losses behind Travelers miss; shares down 1.35% premarket https://seekingalpha.com/news/3279810-weather-losses-behind-travelers-miss-shares-down-1_35-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279810-weather-losses-behind-travelers-miss-shares-down-1_35-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279799\" data-ts=\"1500551302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABYLY\" target=\"_blank\">ABYLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279799-ablynx-and-sanofi-team-up-to-develop-nanobody-based-therapeutics-for-inflammatory-diseases\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ablynx and Sanofi team up to develop Nanobody-based therapeutics for inflammatory diseases; Sanofi up 2% premarket</a></h4><ul><li>Ablynx (<a href='https://seekingalpha.com/symbol/ABYLY' title='Ablynx NV ADR'>OTC:ABYLY</a>) and Sanofi (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) ink a research collaboration and global exclusive license <a href=\"https://seekingalpha.com/pr/16891490-ablynx-sanofi-enter-strategic-collaboration-develop-nanobody-product-candidates-focused\" target=\"_blank\">agreement </a>to develop Nanobody-based therapeutics to treat a range of immune-mediated inflammatory disorders.</li><li>The deal gives Sanofi access to certain Nanobodies in Ablynx's existing portfolio in addition to its scientists and Nanobody platform. Sanofi will have global exclusive rights to certain multi-specific Nanobodies against selected targets, with options for similar rights to additional targets, totalling eight potential product candidates.</li><li>Under the terms of the agreement, Ablynx will receive an upfront payment of &euro;23M, &euro;8M in research funding, up to &euro;2.4B in milestones and up to low-double-digit tiered royalties on net sales.</li><li>SNY is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279799\" data-linked=\"Ablynx and Sanofi team up to develop Nanobody-based therapeutics for inflammatory diseases; Sanofi up 2% premarket\" data-tweet=\"$ABYLY $ABYLY $SNY - Ablynx and Sanofi team up to develop Nanobody-based therapeutics for inflammatory diseases; Sanofi up 2% premarket https://seekingalpha.com/news/3279799-ablynx-and-sanofi-team-up-to-develop-nanobody-based-therapeutics-for-inflammatory-diseases?source=tweet\" data-url=\"https://seekingalpha.com/news/3279799-ablynx-and-sanofi-team-up-to-develop-nanobody-based-therapeutics-for-inflammatory-diseases\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279797\" data-ts=\"1500551212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279797-abbott-laboratories-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abbott Laboratories beats by $0.01, beats on revenue</a></h4><ul><li>Abbott Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>): Q2 EPS of $0.62 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $6.64B (+24.6% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+1.15%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16891698-abbott-reports-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279797\" data-linked=\"Abbott Laboratories beats by $0.01, beats on revenue\" data-tweet=\"$ABT - Abbott Laboratories beats by $0.01, beats on revenue https://seekingalpha.com/news/3279797-abbott-laboratories-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279797-abbott-laboratories-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279794\" data-ts=\"1500551003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGM\" target=\"_blank\">MGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279794-moving-up-to-s-and-p-500-mgm-rmd-pkg-aos-dre\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moving up to the S&amp;P 500: MGM, RMD, PKG, AOS, DRE</a></h4><ul>     <li>MGM&nbsp;Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>) <font color='green'>+2.8%</font> premarket on news it is <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/555951_reynoldsamerican54shuffle.pdf?force_download=true\" target=\"_blank\">joining the S&amp;P 500</a>, replacing Reynolds American (NYSE:<a href='https://seekingalpha.com/symbol/RAI' title='Reynolds American, Inc.'>RAI</a>), effective prior to the open of July 26; British American Tobacco is acquiring RAI.</li>     <li>Also, ResMed (NYSE:<a href='https://seekingalpha.com/symbol/RMD' title='ResMed Inc.'>RMD</a>), Packaging Corp. of America (NYSE:<a href='https://seekingalpha.com/symbol/PKG' title='Packaging Corporation Of America'>PKG</a>), A.O. Smith (NYSE:<a href='https://seekingalpha.com/symbol/AOS' title='A. O. Smith Corporation'>AOS</a>) and Duke Realty (NYSE:<a href='https://seekingalpha.com/symbol/DRE' title='Duke Realty Corp.'>DRE</a>) will move up from the S&amp;P&nbsp;MidCap 400 to replace Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a>), Murphy Oil (NYSE:<a href='https://seekingalpha.com/symbol/MUR' title='Murphy Oil Corporation'>MUR</a>), Bed Bath &amp;&nbsp;Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>) and Transocean (NYSE:<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a>).</li>     <li>All stocks moving up to the S&amp;P 500 have market caps above $10B, and the stocks dropping to the MidCap 400 have market caps below $4.5B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279794\" data-linked=\"Moving up to the S&amp;P 500: MGM, RMD, PKG, AOS, DRE\" data-tweet=\"$MGM $MGM $RAI - Moving up to the S&amp;P 500: MGM, RMD, PKG, AOS, DRE https://seekingalpha.com/news/3279794-moving-up-to-s-and-p-500-mgm-rmd-pkg-aos-dre?source=tweet\" data-url=\"https://seekingalpha.com/news/3279794-moving-up-to-s-and-p-500-mgm-rmd-pkg-aos-dre\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279789\" data-ts=\"1500550450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POOL\" target=\"_blank\">POOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279789-on-pool-corporations-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Pool Corporation&#39;s Q2</a></h4><ul>     <li>Pool (NASDAQ:<a href='https://seekingalpha.com/symbol/POOL' title='Pool Corporation'>POOL</a>)&nbsp;reports&nbsp;base business net sales growth of 7% in <a href=\"https://seekingalpha.com/pr/16891651-pool-corporation-reports-record-second-quarter-results\" target=\"_blank\">Q2</a>.</li>     <li>Gross margin rate slipped 20 bps to 29.3%.</li>     <li>Operating margin rate +10 bps 15.6%.</li>     <li>Adjusted EBITDA grew 9% to $163.78M.</li>     <li>The company reaffirms FY2017 diluted EPS to be in the range of $4.12 to $4.32.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279789\" data-linked=\"More on Pool Corporation&#39;s Q2\" data-tweet=\"$POOL - More on Pool Corporation&#39;s Q2 https://seekingalpha.com/news/3279789-on-pool-corporations-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279789-on-pool-corporations-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279782\" data-ts=\"1500549675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PM\" target=\"_blank\">PM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279782-on-philip-morris-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Philip Morris&#39; Q2</a></h4><ul>     <li>Philip Morris (NYSE:<a href='https://seekingalpha.com/symbol/PM' title='Philip Morris International Inc.'>PM</a>) reports revenue rose 7%&nbsp;if the impact of the currency swings is backed out in <a href=\"https://seekingalpha.com/pr/16891654-philip-morris-international-inc-pmi-reports-2017-second-quarter-results-revises-2017-full\" target=\"_blank\">Q2</a>.</li>     <li>European Union revenue down 2.1% to $2.11B.</li>     <li>Eastern Europe,&nbsp;Middle East&nbsp;&amp;&nbsp;Africa revenue up 0.7% to $1.675B.</li>     <li>Asia revenue expanded 11.8% to $2.384B.</li>     <li>Latin America &amp; Canada revenue grew 7.3% to $748M.</li>     <li>Cigarette shipment volume slipped 7.5% to 193.5B units.</li>     <li>The brands with the highest cigarette shipment volume growth for the quarter were Philip Morris +42.4% and Chesterfield +17.7%.</li>     <li>The company expects diluted EPS of&nbsp;$4.78 to $4.93&nbsp;for FY2017.</li>     <li>\"Our quarterly results were robust with, as expected, sequential improvement in our volume performance, as well as strong currency-neutral net revenue growth of 7% versus last year,\" said&nbsp;Andr&eacute; Calantzopoulos, Chief Executive Officer.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279782\" data-linked=\"More on Philip Morris&#39; Q2\" data-tweet=\"$PM - More on Philip Morris&#39; Q2 https://seekingalpha.com/news/3279782-on-philip-morris-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279782-on-philip-morris-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279774\" data-ts=\"1500548750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BX\" target=\"_blank\">BX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279774-blackstone-misses-0_03-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blackstone misses by $0.03, misses on revenue</a></h4><ul><li>Blackstone (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>): Q2 EPS of $0.59 <font color='red'>misses by $0.03</font>.</li><li>Revenue of $1.51B (+29.1% Y/Y) <font color='red'>misses by $20M</font>.</li><li>Shares <font color='green'>+1.8%</font> PM.</li><li><a href='https://s1.q4cdn.com/641657634/files/doc_financials/2017/q2/Blackstone2Q17EarningsPressRelease.pdf'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279774\" data-linked=\"Blackstone misses by $0.03, misses on revenue\" data-tweet=\"$BX - Blackstone misses by $0.03, misses on revenue https://seekingalpha.com/news/3279774-blackstone-misses-0_03-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279774-blackstone-misses-0_03-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279768\" data-ts=\"1500548184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279768-regulus-prices-stock-offering-0_91-per-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus prices stock offering at $0.91 per share</a></h4><ul><li>Regulus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>) <a href=\"https://seekingalpha.com/pr/16891466-regulus-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 44M shares of common stock at $0.91 per share. Underwriters over-allotment is an additional 6.6M shares. Closing date is July 25.</li><li>Yesterday's close was $0.96.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279649-regulus-readies-equity-offering-shares-3-percent-hours\" target=\"_blank\">Regulus readies equity offering; shares off 3% after hours</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279768\" data-linked=\"Regulus prices stock offering at $0.91 per share\" data-tweet=\"$RGLS - Regulus prices stock offering at $0.91 per share https://seekingalpha.com/news/3279768-regulus-prices-stock-offering-0_91-per-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3279768-regulus-prices-stock-offering-0_91-per-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279751\" data-ts=\"1500546559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PII\" target=\"_blank\">PII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279751-on-polaris-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Polaris&#39; Q2</a></h4><ul>     <li>Polaris (NYSE:<a href='https://seekingalpha.com/symbol/PII' title='Polaris Industries Inc.'>PII</a>)&nbsp;reports&nbsp;North American&nbsp;Off-Road Vehicles&nbsp;unit retail sales were down&nbsp;low-single digits&nbsp;percent&nbsp;in <a href=\"https://seekingalpha.com/pr/16891567-polaris-reports-2017-second-quarter-results\" target=\"_blank\">Q2</a>.</li>     <li>Sales break-up:&nbsp;Off-Road Vehicles/Snowmobiles: $845.51M (+6%); Motorcycles: $198M (-13%);&nbsp;Global adjacent markets: $97.02M (+7%); Aftermarket: $224.39M (+1,755%).</li>     <li>Income from financial services fell 6% to $19.1M.</li>     <li>Adjusted gross margin rate improved 160 bps to 26.8% due&nbsp;to&nbsp;significant gross VIP cost savings and positive product mix.</li>     <li>Operating margin rate slipped 300 bps to 7.3%.</li>     <li>Total dealer inventory was down 6%.</li>     <li><b>FY2017 Guidance</b>: Adjusted sales:&nbsp;+12% to +14%; Adjusted Diluted EPS: $4.35 to $4.5.</li>     <li>PII&nbsp;<font color='green'>+0.05%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279751\" data-linked=\"More on Polaris&#39; Q2\" data-tweet=\"$PII - More on Polaris&#39; Q2 https://seekingalpha.com/news/3279751-on-polaris-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279751-on-polaris-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279737\" data-ts=\"1500544713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UL\" target=\"_blank\">UL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279737-unilever-reports-1h-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unilever reports 1H results</a></h4><ul><li>Unilever (NYSE:<a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>): 1H EPS of&nbsp;&euro;1.13</li><li>Revenue of&nbsp;&euro;27.73B (+5.5% Y/Y)</li><li>Shares <font color='green'>+1.06%</font> PM.</li><li><a href=\"https://www.unilever.com/news/Press-releases/2017/half-year-results-show-profitable-growth-ahead-of-our-markets.html\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279737\" data-linked=\"Unilever reports 1H results\" data-tweet=\"$UL $UN - Unilever reports 1H results https://seekingalpha.com/news/3279737-unilever-reports-1h-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3279737-unilever-reports-1h-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":72,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}